J Biol Regul Homeost Agents. May-Jun 2021; 35(3):843-846. doi: 10.23812/21-20-E.
Management of patients at risk of anaphylaxis after COVID 19 vaccination
- 1 School and Operative Unit of Allergy and Clinical Immunology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
- 2 Division of Hematology, Department of Human Pathology in Adulthood and Childhood “Gaetano Barresi”, University of Messina, Messina, Italy.
- 3 Center Advanced Science and Technology, G. d’Annunzio University, Chieti, Italy.
- 4 Institute for Clinical Immunotherapy and Advanced Biological Treatments, Pescara, Italy.
The success of a vaccination campaign depends on the possibility of guaranteeing not only a wide distribution of effective vaccines, but also on their safety and acceptance by the population. Vaccine safety questions should be answered by correct, unbiased and evidence-based reports, and by addressing all possible problems including allergic reactions. Despite the fact that many COVID-19 vaccines are free from the majority of potentially sensitizing components, an allergic reaction can occur even in the form of a severe, life-threatening anaphylaxis. The frequency of allergic reactions against COVID vaccine is greater than that observed for other vaccinations. National and international allergology societies have proposed specific guidelines for individuals at risk of anaphylaxis by vaccine. Vaccines, like all the pharmaceutical preparations, are submitted to great safety and efficacy valuations, however, even the greatest pre-licensure experimentations are insufficient to evaluate the vaccine’s potential to provoke anaphylaxis. Therefore, post-market surveillance is essential to analyze, record and characterize all adverse events. To this purpose, specific algorithms should be used as a monitoring strategy of adverse events in patients undergoing vaccination against COVID 19.
Copyright 2021 Biolife Sas. www.biolifesas.org.
COVID-19, anaphylaxis, management of allergic reaction, vaccination